Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Nature Biotechnology (227)
Nature Reviews Drug Discovery (6)
Bioentrepreneur (5)
Biopharma Dealmakers (2)
Nature Communications (1)

Choose more journals

Article type Check one or more article types to show results from those article types only.

News (214)
Amendments and Corrections (15)
Comments & Opinion (5)
Special Features (5)
Books & Arts (1)
Research (1)

Subject Check one or more subjects to show results from those subjects only.

Biochemistry
Biological techniques
Biotechnology
Business and industry
Cancer
Cell biology
Chemical biology
Computational biology and bioinformatics
Diseases
Drug discovery
Ecology
Genetics
Health care
Immunology
Medical research
Neuroscience
Oncology
Pathogenesis
Plant sciences
Scientific community

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 151–200 of 241 results

Advanced filters: Author: Cormac Sheridan Clear advanced filters

Why gene therapies must go virus-free

Gene therapies have made spectacular progress in delivering new cures for previously intractable disease, but they remain the world’s most expensive treatments. Now companies are replacing the virus in gene therapies with new delivery technologies that promise not only to overcome the limitations of viral vectors but to slash production costs too.

Cormac Sheridan
News14 Jun 2023
Nature Biotechnology

Volume: 41, P: 737-739
Unprecedented blood biomarker enables ALS drug approval

Biogen’s drug Qalsody is the first drug to gain approval for a genetically defined form of ALS, but there is more to come as developers zoom in on a wide range of disease targets.

Cormac Sheridan
News29 Jun 2023
Nature Biotechnology

Volume: 41, P: 886-888
Questions remain following first COVID-19 vaccine results

CanSino and Moderna are the first vaccine makers to report data on safety and neutralization, but the extent of protection these products afford remains unclear.

Cormac Sheridan
News28 May 2020
Nature Biotechnology
First off-the-shelf mesenchymal stem cell therapy nears European approval

Cormac Sheridan
News06 Mar 2018
Nature Biotechnology

Volume: 36, P: 212-214
Llama-inspired antibody fragment approved for rare blood disorder

Sanofi wins US go-ahead for Ablynx’s nanobody.

Cormac Sheridan
News02 Apr 2019
Nature Biotechnology

Volume: 37, P: 333-334
To win at gene therapy, companies pick viruses with production credentials

Cormac Sheridan
News03 Jan 2019
Nature Biotechnology

Volume: 37, P: 5-6
Convalescent serum lines up as first-choice treatment for coronavirus

Antibodies from blood donated by people who recovered from the illness and hyper-immunoglobulins are becoming treatments of choice for COVID-19, with recombinant polyclonal antibody approaches to follow.

Cormac Sheridan
News01 May 2020
Nature Biotechnology

Volume: 38, P: 655-658
Low-molecular-weight albumin drug touted for severe osteoarthritis

Cormac Sheridan
News05 Apr 2018
Nature Biotechnology

Volume: 36, P: 293
Pancreatic cancer provides testbed for first mechanotherapeutics

Pancreatic cancer treatments are forging the path for a new line of agents that target the physical properties of a tumor and its surrounding microenvironment.

Cormac Sheridan
News12 Jul 2019
Nature Biotechnology

Volume: 37, P: 829-831
PCSK9-gene-silencing, cholesterol-lowering drug impresses

The Medicines Company’s partnered drug uses RNA interference to tackle stubbornly high LDL cholesterol.

Cormac Sheridan
News03 Dec 2019
Nature Biotechnology

Volume: 37, P: 1385-1387
Drug developers switch gears to inhibit STING

Several biotechs are exploring STING inhibitors as a means to control innate immunity and inflammation.

Cormac Sheridan
News04 Mar 2019
Nature Biotechnology

Volume: 37, P: 199-201
Grail of RAS cancer drugs within reach

The first KRAS inhibitors to reach the clinic show preliminary but promising safety and efficacy.

Cormac Sheridan
News09 Jan 2020
Nature Biotechnology

Volume: 38, P: 6-8
Genetic medicines aim straight for the heart

Promising gene therapy, gene editing and antisense oligonucleotide approaches herald a new era of cardiac medicine for patients with certain so-far intractable heart conditions.

Cormac Sheridan
News04 Apr 2023
Nature Biotechnology

Volume: 41, P: 435-437
For hemophilia and thalassemia, a new era of ‘one-and-done’ gene therapies has arrived

Industry celebrates two newly approved genetic medicines, but patients with these blood disorders may face a long wait, and many will never access them because of their high cost.

Cormac Sheridan
News08 Nov 2022
Nature Biotechnology

Volume: 40, P: 1531-1533
Shoot the messenger: RNA editing is here

RNA editing is rapidly gaining prominence as its transient and reversible changes promise a safer and more flexible option to reverse disease-causing mutations than DNA editing.

Cormac Sheridan
News06 Mar 2023
Nature Biotechnology

Volume: 41, P: 306-308
Stem cell controversy to stall European tissue and cell therapy rules

Divergent views among European Union member states on human embryonic stem cell research could hamper the creation of a much awaited new regulatory framework to address the sale and marketing of cell therapies and tissue-engineered products.

Cormac Sheridan
News01 May 2006
Nature Biotechnology

Volume: 24, P: 479-480
European pharma consolidation generates quality spinoffs

Although Bayer Healthcare, headquartered in Leverkusen, Germany, spent most of 2006 in the spotlight because of its €16.3 billion ($19.6 billion) acquisition of Berlin-based Schering, its ongoing restructuring is bound to yield a total of three new German spin-offs to the ranks of Europe's independent life sciences companies.

Cormac Sheridan
News06 Dec 2006
Nature Biotechnology

Volume: 24, P: 1458-1459
Belgian biotech's clot-buster approved for aging eyes

Cormac Sheridan
News07 Dec 2012
Nature Biotechnology

Volume: 30, P: 1158
Cardiac stem cell therapies inch toward clinical litmus test

Cormac Sheridan
News09 Jan 2013
Nature Biotechnology

Volume: 31, P: 5-6
Proof of concept for next-generation nanoparticle drugs in humans

Cormac Sheridan
News07 Jun 2012
Nature Biotechnology

Volume: 30, P: 471-472
First new drug approval for AML in 15 years

Cormac Sheridan
News01 Aug 2017
Nature Biotechnology

Volume: 35, P: 696-698
Small molecule challenges dominance of TNF-α inhibitors

Cormac Sheridan
News01 Feb 2008
Nature Biotechnology

Volume: 26, P: 143-144
Flu virus lapses shows quantum leap in technologies needed

Developing treatments that would calm pandemic fears need more funding and resources.

Cormac Sheridan
News01 Jun 2005
Nature Reviews Drug Discovery

Volume: 4, P: 447
Production technologies change flu vaccine landscape

The first flu vaccine made in cell culture meets with the approval of the EMEA, as others move through company pipelines.

Cormac Sheridan
News02 Jul 2007
Nature Biotechnology

Volume: 25, P: 701
Insomniacs get new mechanism sleep drug Belsomra

Cormac Sheridan
News09 Oct 2014
Nature Biotechnology

Volume: 32, P: 968
Calamitous HCV trial casts shadow over nucleoside drugs

Cormac Sheridan
News08 Nov 2012
Nature Biotechnology

Volume: 30, P: 1015-1016
Cord blood cell therapy trial suspended

Umbilical cord blood stem cell therapies used in the treatment of blood cancers are forging ahead, but it's an uphill struggle.

Cormac Sheridan
News06 Dec 2005
Nature Biotechnology

Volume: 23, P: 1455-1456
Hemophilia market awaits next-generation therapies

Cormac Sheridan
News08 Nov 2011
Nature Biotechnology

Volume: 29, P: 960
Europe lags, US leads 2nd-generation biofuels

Cormac Sheridan
News01 Dec 2008
Nature Biotechnology

Volume: 26, P: 1319-1320
Cancer centers zero in on exceptional responders

Cormac Sheridan
News07 Aug 2014
Nature Biotechnology

Volume: 32, P: 703-704
Antiinfective biotechs face partnering gap

The big pharmaceutical companies are increasingly withdrawing from the fight against multidrug-resistant bacteria. Biotech companies have taken a step to replace them but they may not have enough experience of developing new drugs to provide the next generation of antiinfectives.

Cormac Sheridan
News01 Feb 2005
Nature Biotechnology

Volume: 23, P: 155-156
Firms combine experimental cancer drugs to speed development

Cormac Sheridan
News01 Aug 2010
Nature Biotechnology

Volume: 28, P: 765-766
Safety profiles come to fore as more drugs approach MS market

Cormac Sheridan
News09 Jan 2012
Nature Biotechnology

Volume: 30, P: 6-8
Immuno-oncology moves beyond PD-1

Cormac Sheridan
News08 Jul 2015
Nature Biotechnology

Volume: 33, P: 673-675
Tysabri raises alarm bells on drug class

Although the financial implications of Elan's and Biogen Idec's shock withdrawal from the market of the highly promising multiple sclerosis drug Tysabri were immediate and dramatic, it could have long-term consequences on the whole class of drug as companies developing drugs with a similar mechanism of action as Tysabri had to suspend their trials.

Cormac Sheridan
News01 Apr 2005
Nature Biotechnology

Volume: 23, P: 397-398
Stem cell therapy clears first hurdle in AMD

Cormac Sheridan
News09 Dec 2014
Nature Biotechnology

Volume: 32, P: 1173-1174
Protein chip companies turn to biomarkers

A new proteomics chip claims to allow high throughput protein-interaction studies used in drug discovery.

Cormac Sheridan
News01 Jan 2005
Nature Biotechnology

Volume: 23, P: 3-4
Genentech obtains proof of concept for hedgehog inhibition

Cormac Sheridan
News01 Nov 2009
Nature Biotechnology

Volume: 27, P: 968-969
First generic biologics finally approved

Cormac Sheridan
News01 Jun 2006
Nature Reviews Drug Discovery

Volume: 5, P: 445
Tysabri risk causing headache for companies

Cormac Sheridan
News01 Sept 2005
Nature Reviews Drug Discovery

Volume: 4, P: 703-704
Report blames GM crops for herbicide spike, downplays pesticide reductions

Cormac Sheridan
News01 Feb 2010
Nature Biotechnology

Volume: 28, P: 112-113
Living and dying with viruses

Cormac Sheridan
Books & Arts01 Jan 2005
Nature Biotechnology

Volume: 23, P: 25
Grail to pour $1 billion into blood test to detect early cancer

Cormac Sheridan
News08 Feb 2017
Nature Biotechnology

Volume: 35, P: 101-102
Politics torpedo biotech as EU priority

Ambitious plans by the European Commission (EC) to double research spending during 2007–2013 were quietly shelved during the run-up to a political summit of EU heads of state on June 15–16.

Cormac Sheridan
News01 Jul 2005
Nature Biotechnology

Volume: 23, P: 766-767
CETP inhibitors boost 'good' cholesterol to no avail

Cormac Sheridan
News01 Jan 2016
Nature Biotechnology

Volume: 34, P: 5-6
First integrin inhibitor since Tysabri nears approval for IBD

Cormac Sheridan
News10 Mar 2014
Nature Biotechnology

Volume: 32, P: 205-206
Investors start backing hearing loss treatments

Cormac Sheridan
News09 Jul 2013
Nature Biotechnology

Volume: 31, P: 575-576
Benefits of biotech clusters questioned

Cormac Sheridan
News01 Nov 2003
Nature Biotechnology

Volume: 21, P: 1258-1259
Anti-CD20 antibody wows in multiple sclerosis

Cormac Sheridan
News09 Dec 2015
Nature Biotechnology

Volume: 33, P: 1215-1216
Can 'double blockbuster' strengthen Amgen's backbone?

Cormac Sheridan
News01 Apr 2008
Nature Biotechnology

Volume: 26, P: 361-362